NDC 64842-0727 Inqovi

Cedazuridine And Decitabine Tablet, Film Coated Oral - View Dosage, Usage, Ingredients, Routes, UNII

Product Information

NDC Product Code:
64842-0727
Proprietary Name:
Inqovi
Non-Proprietary Name: [1]
Cedazuridine And Decitabine
Substance Name: [2]
Cedazuridine; Decitabine
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Dosage Form:
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route(s): [4]
  • Oral - Administration to or by way of the mouth.
  • Labeler Name: [5]
    Taiho Pharmaceutical Co., Ltd.
    Labeler Code:
    64842
    FDA Application Number: [6]
    NDA212576
    Marketing Category: [8]
    NDA - A product marketed under an approved New Drug Application.
    Start Marketing Date: [9]
    07-07-2020
    Listing Expiration Date: [11]
    12-31-2024
    Exclude Flag: [12]
    N
    Code Structure:
    Code Navigator:

    Product Characteristics

    Color(s):
    RED (C48326)
    Shape:
    OVAL (C48345)
    Size(s):
    14 MM
    Imprint(s):
    H35
    Score:
    1

    Product Packages

    NDC Code 64842-0727-9

    Package Description: 1 BLISTER PACK in 1 CARTON / 5 TABLET, FILM COATED in 1 BLISTER PACK

    Product Details

    What is NDC 64842-0727?

    The NDC code 64842-0727 is assigned by the FDA to the product Inqovi which is a human prescription drug product labeled by Taiho Pharmaceutical Co., Ltd.. The generic name of Inqovi is cedazuridine and decitabine. The product's dosage form is tablet, film coated and is administered via oral form. The product is distributed in a single package with assigned NDC code 64842-0727-9 1 blister pack in 1 carton / 5 tablet, film coated in 1 blister pack. This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

    What are the uses for Inqovi?

    INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

    What are Inqovi Active Ingredients?

    An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
    • CEDAZURIDINE 100 mg/1
    • DECITABINE 35 mg/1 - An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.

    Which are Inqovi UNII Codes?

    The UNII codes for the active ingredients in this product are:

    Which are Inqovi Inactive Ingredients UNII Codes?

    The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

    What is the NDC to RxNorm Crosswalk for Inqovi?

    RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
    • RxCUI: 2384457 - cedazuridine 100 MG / decitabine 35 MG Oral Tablet
    • RxCUI: 2384458 - {5 (cedazuridine 100 MG / decitabine 35 MG Oral Tablet) } Pack
    • RxCUI: 2384458 - cedazuridine 100 MG / decitabine 35 MG (5) Oral Tablet Pack
    • RxCUI: 2384464 - INQOVI 35 MG / 100 MG Oral Tablet
    • RxCUI: 2384464 - cedazuridine 100 MG / decitabine 35 MG Oral Tablet [Inqovi]

    Which are the Pharmacologic Classes for Inqovi?

    A pharmacologic class is a group of drugs that share the same scientifically documented properties. The following is a list of the reported pharmacologic class(es) corresponding to the active ingredients of this product.

    * Please review the disclaimer below.

    Patient Education

    Decitabine and Cedazuridine


    The combination of decitabine and cedazuridine is used to treat certain types of myelodysplastic syndrome (conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells), including chronic myelomonocytic leukemia (CMML) in adults. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect.
    [Learn More]


    * Please review the disclaimer below.

    Product Footnotes

    [1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

    [2] What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

    [3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

    [4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.

    [5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

    [6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

    [8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

    [9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

    [11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

    [12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".